Compare CION & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CION | ABEO |
|---|---|---|
| Founded | 2011 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.2M | 282.5M |
| IPO Year | 2011 | 2005 |
| Metric | CION | ABEO |
|---|---|---|
| Price | $6.01 | $2.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $8.75 | ★ $15.56 |
| AVG Volume (30 Days) | 424.3K | ★ 2.1M |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | ★ 19.70% | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $675.42 |
| Revenue Next Year | N/A | $126.99 |
| P/E Ratio | $17.55 | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $5.83 | $2.09 |
| 52 Week High | $10.40 | $7.65 |
| Indicator | CION | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 35.12 | 25.77 |
| Support Level | $5.90 | N/A |
| Resistance Level | $7.25 | $5.77 |
| Average True Range (ATR) | 0.23 | 0.33 |
| MACD | -0.06 | -0.15 |
| Stochastic Oscillator | 12.40 | 18.75 |
CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Companies portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.